NCT01252745View on ClinicalTrials.gov

Efficacy of an Intranasal Testosterone Product

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

December 31, 2010

Conditions
Hypogonadism
Interventions
DRUG

10.0 mg of Testosterone, 4.0% TID

DRUG

13.5 mg of Testosterone, 4.5% B.I.D

DRUG

11.25 mg of Testosterone, 4.5% T.I.D

Trial Locations (3)

Unknown

Quality of Life Medical and Research Center, Tucson

Pharmax Research Clinic Inc., Miami

Regional Urology LLC, Shreveport

Sponsors
All Listed Sponsors
lead

Acerus Pharmaceuticals Corporation

INDUSTRY